Article

From the Literature: Depression

Review the key findings of three recent studies looking at online therapy and longstanding disease in depression.

Cost-effectiveness of Therapist-delivered Online Cognitive-behavioural Therapy for Depression: Randomised Controlled Trial

Journal: The British Journal of Psychiatry (October 2010)

Authors: Hollinghurst S, Peters T, Kaur S, et al.

Purpose: To compare usual care to cognitive-behavioral therapy in regards to cost-effectiveness.

Results: When compared with usual care, online cognitive-behavioral therapy delivered in real time by a therapist is likely to be cost-effective as long as society is willing to pay roughly $32,000 per quality-adjusted life-years.

Click here to access this third-party resource.

Internet-delivered Psychotherapy for Depression in Adults

Journal: Current Opinion in Psychiatry (September 4, 2010)

Author: Titov N

Purpose: To review the current status of Internet-delivered psychotherapy (iPT) for treating adults with depression symptoms.

Results: “Recent studies indicate the utility of iPT. Large-scale trials are needed to evaluate optimal strategies for disseminating iPT. Future studies should independently replicate findings and efforts are required to educate patients and health professionals about iPT.”

Click here to access this third-party resource.

Longstanding Disease, Disability or Infirmity and Depression in Primary Care

Journal: Wiener Klinische Wochenschrift (October 1, 2010)

Authors: Rifel J, Svab I, Rotar D, et al.

Purpose: “To assess the prevalence and incidence of depression and likelihood for new-onset depression in patients with self-reported longstanding disease, disability or infirmity in the sample of primary care attendees.”

Results: Among those who reported longstanding disease, prevalence of major depression was 8.9%, compared to a prevalence of 3.1% among those without longstanding disease. Also, among the former group, major depression incidence after 6 months was 2.7%, compared with 0.9% among the latter. Further, patients who had longstanding disease at baseline were nearly four times more like to have major depression at 6 months than participants without longstanding disease at baseline. The authors concluded that these associations are important in the primary care setting.

Click here to access this third-party resource.

Related Videos
Jonathan Meyer, MD: Cognitive Gains, Dopamine-Free Schizophrenia Treatment with Xanomeline Trospium Chloride
Chelsie Monroe: Challenges Clinicians Should Consider When Prescribing Muscarinic Modulators for Schizophrenia
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
Thumbnail for schizophrenia special report around approval of Cobenfy.
© 2024 MJH Life Sciences

All rights reserved.